Silver Book Fact

Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.

Lasker Foundation. Exceptional Returns: The economic value of America’s investment in medical research. 2000; https://www.medscape.com/viewarticle/447944

Reference

Title
Exceptional Returns: The economic value of America’s investment in medical research
Publisher
Funding First
Publication Date
2000
Authors
Lasker Foundation
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.